Literature DB >> 15133273

Anemia with chronic renal disorder and disrupted metabolism of erythropoietin in ICR-derived glomerulonephritis (ICGN) mice.

Misuzu Yamaguchi-Yamada1, Noboru Manabe, Kozue Uchio-Yamada, Naotsugu Akashi, Yasufumi Goto, Youhei Miyamoto, Masaya Nagao, Yoshie Yamamoto, Atsuo Ogura, Hajime Miyamoto.   

Abstract

The ICR-derived glomerulonephritis (ICGN) mouse, a new inbred mouse strain with a hereditary nephrotic syndrome, is considered to be a good model of human idiopathic nephrotic syndrome and notably exhibits proteinuria and hypoproteinemia from the neonatal stage. In chronic renal disorder (CRD), anemia is a major subsequent symptom (renal anemia). The precise cause of renal anemia remains unclear, primarily owing to the lack of appropriate spontaneous animal models for CRD. To establish adequate animal models for anemia with CRD, we examined the hematological-biochemical properties and histopathological characteristics. With the deterioration of renal function, ICGN mice developed a normochromic and normocytic anemia, and exhibited normochromic and microcytic at the terminal stage. The expression of erythropoietin (EPO) mRNA both in the kidneys and liver and the EPO leak into the urine were observed in ICGN mice, indicating a disrupted metabolism of EPO in ICGN mice. In addition, a lack of iron induced by the hemolysis in the spleen and the leak of transferrin into urine as proteinuria aggravated the anemic condition. In conclusion, the ICGN mouse is a good model for anemia with CRD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133273     DOI: 10.1292/jvms.66.423

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  2 in total

Review 1.  Anemia in nephrotic syndrome: approach to evaluation and treatment.

Authors:  Franca Iorember; Diego Aviles
Journal:  Pediatr Nephrol       Date:  2016-12-21       Impact factor: 3.714

2.  Renal Function and Hematology in Rats with Congenital Renal Hypoplasia.

Authors:  Hidenori Yasuda; Kohei Amakasu; Yuki Tochigi; Kentaro Katayama; Hiroetsu Suzuki
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.